How Do Glucocorticoids Used in Rheumatic Disease Affect Body Weight? A Narrative Review of the Evidence.
Catharine MorganRuth E CostelloDavid W RayWilliam Gregory DixonPublished in: Arthritis care & research (2020)
Glucocorticoids (GCs) are widely used to effectively treat inflammatory disease, but GCs have a number of recognized side effects. Patients and clinicians view these side effects differently, with clinicians most concerned with serious side effects such as osteoporosis and diabetes mellitus. Consequently, these side effects are well researched with clinical guidelines and recommendations. A side effect of particular concern to patients is weight gain, but this topic has not been well researched, and consequently clinicians find it difficult to provide patients with accurate information about the potential of weight gain. The aim of this review is to provide an overview of GC use specifically in rheumatic disease, patient views on GC therapy, and GC-induced weight gain. We will discuss the evidence, including the extent and the impact of weight gain on the patient, and highlight areas that warrant further investigation.
Keyphrases
- weight gain
- body mass index
- birth weight
- end stage renal disease
- ejection fraction
- weight loss
- newly diagnosed
- chronic kidney disease
- palliative care
- prognostic factors
- type diabetes
- clinical practice
- stem cells
- oxidative stress
- adipose tissue
- patient reported outcomes
- risk assessment
- endothelial cells
- bone mineral density
- physical activity
- mass spectrometry
- drug induced
- insulin resistance
- stress induced
- skeletal muscle
- simultaneous determination
- diabetic rats
- health information